Placental transfer of SSRI and SNRI antidepressants and effects on the neonate

Pharmacopsychiatry

Volumn 42, Issue 3, 2009, Pages 95-100

  Rampono, J ^a   Simmer, K ^a,b   Ilett, K F ^c,d   Hackett, L P ^d   Doherty, D A ^b   Elliot, R ^a   Kok, C H ^a   Coenen, A ^a   Forman, T ^a  

^a KING EDWARD MEMORIAL HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d Path West Laboratory Medicine   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; DESMETHYLESCITALOPRAM; DESVENLAFAXINE; DRUG METABOLITE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; NORCITALOPRAM; NORFLUOXETINE; NORSERTRALINE; PAROXETINE; SEROTONIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; UNCLASSIFIED DRUG; VENLAFAXINE; ANTIDEPRESSANT AGENT;

ABSTINENCE; ADULT; ARTICLE; AUTONOMIC NERVOUS SYSTEM; BEHAVIOR; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG BLOOD LEVEL; ENVIRONMENTAL EXPOSURE; FEMALE; FETUS CIRCULATION; HABITUATION; HUMAN; MOTOR PERFORMANCE; NEWBORN; OUTCOME ASSESSMENT; PERINATAL PERIOD; PLACENTAL TRANSFER; PREGNANCY; PRIORITY JOURNAL; SOCIAL INTERACTION; UMBILICAL CORD BLOOD; BLOOD; CHILD BEHAVIOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; FETOMATERNAL TRANSFUSION; FETUS BLOOD; PREGNANCY OUTCOME; PROSPECTIVE STUDY; WITHDRAWAL SYNDROME;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSIVE DISORDER; FEMALE; FETAL BLOOD; HUMANS; INFANT BEHAVIOR; INFANT, NEWBORN; MATERNAL-FETAL EXCHANGE; NEONATAL ABSTINENCE SYNDROME; PREGNANCY; PREGNANCY OUTCOME; PROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS;

EID: 68149178329     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0028-1103296     Document Type: Article

References (42)

1. Agut-Quijano T, Martinez-Nadal S, Elizari-Saco MJ et al. Neonatal withdrawal syndrome to selective serotonin reuptake inhibitors: case report and literature review. Rev Neurol 2006 ; 42 : 660-662
2. Bakker MK, Kolling P, Berg PB van den et al. Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from The Netherlands. Br J Clin Pharmacol 2008 ; 65 : 600-606
3. Begg EJ, Duff ull SB, Saunders DA et al. Paroxetine in human milk. Br J Clin Pharmacol 1999 ; 48 : 142-147
4. Bellantuono C, Migliarese G, Gentile S. Serotonin reuptake inhibitors in pregnancy and the risk of major malformations: a systematic review. Hum Psychopharmacol 2007 ; 22 : 121-128
5. Brazelton TB, Nugent JK. Neonatal behavioral assessment scale. 3rd edn. London, UK: Mac Keith Press ; 1995
6. Casper RC, Fleisher BE, Lee-Ancajas JC et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr 2003 ; 142 : 402-408
7. Challis J, Sloboda D, Matthews S et al. Fetal hypothalamic-pituitary adrenal (HPA) development and activation as a determinant of the timing of birth, and of postnatal disease. Endocr Res 2000 ; 26 : 489-504
8. Chambers CD, Hernandez-Diaz S, Marter LJ Van et al. Selective serotonin- reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. New Engl J Med 2006 ; 354 : 579-587 (Pubitemid 43209105)
9. Chambers CD, Johnson KA, Dick LM et al. Birth outcomes in pregnant women taking fl uoxetine. New Engl J Med 1996 ; 335 : 1010-1015
10. Cox JL, Holden JM, Sagovsky R. Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale. Brit J Psychiatry 1987 ; 150 : 782-786
11. Moor RA de, Mourad L, ter HJ et al. Withdrawal symptoms in a neonate following exposure to venlafaxine during pregnancy. Ned Tijdschr Geneeskd 2003 ; 147 : 1370-1372 (Pubitemid 36850693)
12. Dietz PM, Williams SB, Callaghan WM et al. Clinically identifi ed maternal depression before, during, and after pregnancies ending in live births. Am J Psychiatry 2007 ; 164 : 1515-1520
13. Ferreira E, Carceller AM, Agogue C et al. Eff ects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates. Pediatrics 2007 ; 119 : 52-59
14. Finnegan LP, Connaughton JF Jr, Kron RE et al. Neonatal abstinence syndrome: assessment and management. Addictive Dis 1975 ; 2 : 141-158
15. Heikkinen T, Ekblad U, Kero P et al. Citalopram in pregnancy and lactation. Clin Pharmacol Ther 2002 ; 72 : 184-191
16. Heikkinen T, Ekblad U, Palo P et al. Pharmacokinetics of fl uoxetine and norfl uoxetine in pregnancy and lactation. Clin Pharmacol Ther 2003 ; 73 : 330-337
17. Hendrick V, Stowe ZN, Altshuler LL et al. Placental passage of antidepressant medications. Am J Psychiatry 2003 ; 160 : 993-996
18. Hostetter A, Ritchie JC, Stowe ZN. Amniotic fl uid and umbilical cord blood concentrations of antidepressants in three women. Biol Psychiatry 2000 ; 48 : 1032-1034
19. Ilett KF, Hackett LP, Dusci LJ et al. Distribution and excretion of venlafaxine and O-desmethylvenlafaxine in human milk. Br J Clin Pharmacol 1998 ; 45 : 459-462
20. Isbister GK, Dawson A, Whyte IM et al. Neonatal paroxetine withdrawal syndrome or actually serotonin syndrome? Arch Dis Child Fetal Neonatal Ed 2001 ; 85 : F147-F148
21. Koren G, Moretti M, Kapur B. Can venlafaxine in breast milk attenuate the norepinephrine and serotonin reuptake neonatal withdrawal syndrome. J Obstet Gynaecol Can 2006 ; 28 : 299-302
22. Kristensen JH, Hackett LP, Kohan R et al. The amount of fl uvoxamine in milk is unlikely to be a cause of adverse eff ects in breastfed infants. J Hum Lact 2002 ; 18 : 139-143
23. Kristensen JH, Ilett KF, Dusci LJ et al. Distribution and excretion of sertraline and N-desmethylsertraline in human milk. Br J Clin Pharmacol 1998 ; 45 : 453-457
24. Kristensen JH, Ilett KF, Hackett LP et al. Distribution and excretion of fl uoxetine and norfl uoxetine in human milk. Br J Clin Pharmacol 1999 ; 48 : 521-527
25. Laine K, Heikkinen T, Ekblad U et al. Eff ects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry 2003 ; 60 : 720-726
26. Lane R, Baldwin D. Selective serotonin reuptake inhibitor-induced serotonin syndrome: review. J Clin Psychopharmacol 1997 ; 17 : 208-221
27. Levinson-Castiel R, Merlob P, Linder N et al. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med 2006 ; 160 : 173-176
28. Moses-Kolko EL, Bogen D, Perel J et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 2005 ; 293 : 2372-2383 (Pubitemid 40676760)
29. Oberlander TF, Grunau RE, Fitzgerald C et al. Pain reactivity in 2- month-old infants after prenatal and postnatal serotonin reuptake inhibitor medication exposure. Pediatrics 2005 ; 115 : 411-425
30. Oberlander TF, Warburton W, Misri S et al. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 2006 ; 63 : 898-906
31. Pakalapati RK, Bolisetty S, Austin MP et al. Neonatal seizures from in utero venlafaxine exposure. J Paediatr Child Health 2006 ; 42 : 737-738
32. Pearlstein T. Perinatal depression: treatment options and dilemmas. J Psychiatry Neurosci 2008 ; 33 : 302-318
33. Pirec V. Current dilemmas in treating depressed pregnant patients. Psychopharm Rev 2007 ; 42 : 91-98
34. Rampono J, Hackett LP, Kristensen JH et al. Transfer of escitalopram and its metabolite demethylescitalopram into breastmilk. Br J Clin Pharmacol 2006 ; 62 : 316-322
35. Rampono J, Kristensen JH, Hackett LP et al. Citalopram and demethylcitalopram in human milk; distribution, excretion and eff ects in breast fed infants. Br J Clin Pharmacol 2000 ; 50 : 263-268
36. Rampono J, Proud S, Hackett LP et al. A pilot study of newer antidepressant concentrations in cord and maternal serum and possible eff ects in the neonate. Int J Neuropsychopharmacol 2004 ; 7 : 329-334
37. Rosack J. FDA Committee urges new warning on antidepressants for pregnancy. Psychiatr News 2004 ; 39 : 33
38. Salvia-Roiges MD, Garcia L, Gonce-Mellgren A et al. Neonatal convulsions and subarachnoid hemorrhage after in utero exposure to paroxetine. Rev Neurol 2003 ; 36 : 724-726
39. Stiskal JA, Kulin N, Koren G et al. Neonatal paroxetine withdrawal syndrome. Arch Dis Child Fetal Neonatal Ed 2001 ; 84 : F134-F135
40. Suri R, Altshuler L, Hellemann G et al. Eff ects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth. Am J Psychiatry 2007 ; 164 : 1206-1213
41. Topliss D, Isaccs D, Lander C et al. Maternal SSRI use and neonatal eff ects. Aust Adverse Drug React Bull 2003 ; 22 : 14
42. Zeskind PS, Stephens LE. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics 2004 ; 113 : 368-375